Sunday 18 October 2026
Export SEER’s income statement to Excel — free account
Seer, Inc.
SEER Healthcare Biotechnology
Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.03
0.01
−0.49%
Follow SEER
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 4 | 4 | 3 | 5 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 42.30 | 23.13 | 5.09 | 1.04 | 0.63 | (0.55) |
P/S ratio |
— | — | 1,536.28 | 2,044.75 | 209.81 | 23.57 | 7.43 | 10.16 | 6.34 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 20.40 | 47.70 | 17.77 | 14.34 | 11.48 | 7.75 | 4.62 |
P/Operating CF |
— | — | (105.78) | (244.55) | (112.24) | (25.62) | (12.16) | (12.57) | (9.73) |
Beneish M-Score |
— | — | — | 0.62 | 56.54 | (1.92) | (2.18) | (3.28) | (2.98) |
P/B ratio |
— | — | 0.00 | 3.11 | 2.76 | 0.82 | 0.31 | 0.44 | 0.41 |
Price to Tangible BV |
— | — | 0.00 | 3.11 | 2.76 | 0.82 | 0.31 | 0.44 | 0.41 |
EV/Sales |
— | — | 1,308.71 | 1,386.42 | 149.35 | (3.61) | (11.55) | (6.52) | (4.87) |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.60 | 1.76 | 1.02 | 1.14 |
EV/Operating CF |
— | — | (17.41) | (43.67) | (21.32) | 0.92 | 3.26 | 2.00 | 1.82 |
EV/FCF |
— | — | (13.39) | (35.86) | (18.55) | 0.79 | 2.90 | 1.87 | 1.77 |
Quick Ratio |
— | 8.40 | 22.63 | 53.39 | 30.11 | 34.03 | 24.42 | 15.83 | 12.23 |
Current Ratio |
— | 8.46 | 22.75 | 53.51 | 30.67 | 34.57 | 25.00 | 16.53 | 12.84 |
Net Debt/EBITDA |
— | 4.65 | 5.23 | 13.59 | 5.91 | 4.48 | 2.89 | 2.60 | 2.63 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.04 | 0.04 | 0.05 |
Operating CF/Net income |
— | 0.74 | 0.82 | 0.64 | 0.65 | 0.65 | 0.68 | 0.53 | 0.60 |
Capex/Depreciation |
— | 0.00 | (9.35) | (2.43) | (1.84) | (3.25) | 1.22 | (0.35) | (0.16) |
Interest Coverage |
— | (29.97) | (3,376.60) | (38.11) | (3,248.77) | (21.13) | — | — | — |
| — | 48.31% | 122.84% | (15.94%) | (15.23%) | (19.57%) | (20.45%) | (23.91%) | (25.08%) | |
| — | (37.43%) | (25.27%) | (12.24%) | (14.50%) | (18.10%) | (18.67%) | (21.57%) | (22.21%) | |
ROIC |
— | 0.00% | (636.04%) | 0.00% | (43.44%) | (235.97%) | (80.15%) | (68.63%) | (66.40%) |
Return on Tangible Assets |
— | (21.11%) | (18.09%) | (7.56%) | (17.30%) | (21.04%) | (25.41%) | (33.75%) | (36.69%) |
Average Days of Receivables |
— | 0.00 | 1,025.78 | 145.78 | 228.59 | 165.34 | 147.13 | 160.45 | 131.05 |
Research and Development Expense of Revenue |
— | 0.00% | 10,683.62% | 2,887.50% | 440.09% | 295.60% | 318.22% | 356.99% | 264.65% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 3,970.69% | 2,341.92% | 691.61% | 377.79% | 353.82% | 399.23% | 256.86% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 1,342.24% | 1,120.12% | 391.82% | 217.34% | 206.61% | 199.06% | 92.98% |
Graham Net Nets |
— | — | 0.15 | 0.31 | 0.27 | 1.08 | 2.35 | 1.49 | 1.57 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (3.76%) | (4.60%) | (5.09%) | (25.47%) | (70.10%) | (60.17%) | (69.95%) |
Free Cash Flow Yield |
— | — | (6.36%) | (1.89%) | (3.84%) | (19.41%) | (53.58%) | (34.27%) | (43.37%) |
Revenue per Share |
— | 0.00 | 0.02 | 0.05 | 0.11 | 0.25 | 0.26 | 0.23 | 0.29 |
Operating CF per Share |
— | (0.08) | (1.88) | (1.58) | (0.76) | (0.97) | (0.93) | (0.74) | (0.77) |
Capex per Share |
— | 0.00 | (0.59) | (0.34) | (0.11) | (0.16) | (0.11) | (0.05) | (0.02) |
Free Cash Flow per Share |
— | (0.08) | (2.47) | (1.92) | (0.88) | (1.14) | (1.04) | (0.79) | (0.79) |
Cash per Share |
— | 0.51 | 12.37 | 32.68 | 6.57 | 6.75 | 4.95 | 3.79 | 3.24 |
Shareholders Equity per Share |
— | 0.49 | 12.61 | 32.66 | 8.26 | 7.16 | 6.22 | 5.25 | 4.51 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.49 | 12.61 | 32.66 | 8.26 | 7.16 | 6.22 | 5.25 | 4.51 |
Free Cash Flow |
— | (4.65) | (17.20) | (25.36) | (53.27) | (70.87) | (66.37) | (49.35) | (45.60) |
Working Capital |
— | 27.52 | 82.99 | 425.03 | 398.28 | 422.40 | 317.29 | 238.00 | 185.84 |
Capital Expenditures |
— | (0.17) | (4.13) | (4.53) | (6.92) | (10.09) | (7.31) | (3.24) | (1.15) |
Net Current Asset Value |
— | 27.49 | 81.25 | 422.42 | 375.48 | 394.05 | 291.15 | 214.30 | 164.76 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.58 | 1.86 | 0.92 | 1.04 |
Capex to Sales |
— | — | 35.61 | 6.91 | 1.05 | 0.65 | 0.44 | 0.23 | 0.07 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.01 | 0.08 | 0.22 | 0.29 | 0.16 | (0.27) | 0.50 | 0.49 |
Cash ROIC |
— | (7.63%) | (9.90%) | (2.94%) | (5.90%) | (8.16%) | (9.31%) | (8.75%) | (10.24%) |
Accounts Receivable Turnover |
— | 0.00 | 0.59 | 2.23 | 3.00 | 2.78 | 2.43 | 2.19 | 2.72 |
Accounts Payable Turnover |
— | 0.06 | 0.42 | 0.00 | 1.09 | 2.85 | 4.69 | 2.38 | 1.59 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 1.37 | 1.92 | 1.79 | 1.19 | 1.07 |
Average Days of Payables |
— | 9,581.25 | 365.00 | 0.00 | 431.51 | 91.42 | 61.32 | 237.06 | 252.44 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 472.05 | 201.05 | 201.01 | 381.47 | 350.69 |
Average Receivables |
— | 0.20 | 0.20 | 0.29 | 2.20 | 5.58 | 6.87 | 6.47 | 6.09 |
Average Payables |
— | 1.66 | 1.66 | 1.41 | 2.95 | 2.95 | 1.74 | 3.00 | 5.12 |
Average Inventory |
— | — | — | 2.35 | 2.35 | 4.39 | 4.56 | 5.96 | 7.62 |
Average Assets |
— | 16.85 | 63.47 | 267.78 | 490.73 | 513.53 | 462.10 | 401.43 | 331.34 |
Average Common Equity |
— | (13.06) | (13.06) | 205.67 | 467.26 | 474.95 | 421.95 | 362.24 | 293.44 |
Columns are period end dates